Transcatheter Valve Articles & Analysis: Older
44 news found
Confluent partners with leading OEMs to create a selective product portfolio which includes such complex applications as transcatheter heart valves, neurovascular implants, endovascular stent grafts, and advanced smart catheters. ...
Keystone Heart was acquired in 2018 by Venus Medtech, the leader in transcatheter structural heart valvular therapies in China. Before that, Richardson was International President and Chief Commercial Officer of Direct Flow Medical, a transcatheter aortic valve company, and General Manager of Evalve (MitraClip), which was acquired by Abbott ...
BySafeHeal
The other studies used Zio XT for low-risk patients to screen for atrial fibrillation in patients aged 70 years and older, and Zio AT for high-risk patients to monitor for arrhythmias in patients after transcatheter aortic valve replacement. J.P. Morgan analysts in a Monday note said that "a greater body of evidence supporting the technology will be key as the ...
One in five patients experience a bleeding complication during large-bore endovascular procedures such as transcatheter aortic valve replacement (TAVR), endovascular aneurysm repair (EVAR) and percutaneous mechanical circulatory support. ...
“I am excited to join the talented team at InnovHeart at this pivotal time of focus and commitment to significantly advancing Transcatheter Mitral Valve Replacement (TMVR) procedures enabled by our transformational Saturn platform,” said Mr. ...
Milan, January 27, 2022 – InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an exclusive licensing agreement to Grand Pharmaceutical Group Limited, (Grand Pharma) for its proprietary Saturn ...
This is a 170% greater improvement than observed in studies of other TAVR valves(3). This indicates a marked improvement in patients’ functional status and exercise tolerance. ...
(“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced a strategic investment and exclusive technology licensing agreement with Peijia Medical Limited (HKEX: 9996) in China. ...
Confluent partners with leading OEMs to create a selective product portfolio which includes such complex applications as transcatheter heart valves, neurovascular implants, endovascular stent grafts and advanced smart catheters. ...
” Approximately one in every five patients will experience a bleeding complication during large-bore endovascular procedures such as transcatheter aortic valve replacement (TAVR), endovascular aneurysm repair (EVAR), and percutaneous MCS1. ...
The study was carried out at the Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia. The transcatheter aortic valve replacement procedures for all five patients were successful and without any complications. ...
JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the first commercial implants with the Trilogy Heart Valve System in Europe. ...
Together with him, we have evaluated in which part of a transcatheter heart valve implantation our navigation technology could provide benefits. ...
“And even more exciting is to have the allowance for other transcatheter valve therapy in the 2021 ESC valve guidelines with the Carillon device the only other device mentioned for use. ...
During his 30-year career, he has acquired a unique expertise in implantable cardiac devices. Former VP RAQACA of CardiAQ Valve Technologies, a transcatheter valve start-up acquired by Edwards Lifesciences for $350 million, he has also developed an extensive knowledge of cardiac assist devices (first at Arrow, then at Abbott as a consultant) and ...
ByCorWave
JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced FDA approval for the company to initiate its Investigational Device Exemption (IDE) PMA clinical trial for the Trilogy™ Heart Valve System for severe symptomatic, high-surgical risk aortic ...
JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve implantation (TAVI) systems (also referred to as TAVR, or transcatheter aortic valve replacement) for the treatment of aortic valve disease, today announced that it has received CE Mark for its TrilogyTM Heart ...
These have included rigorous clinical outcome analysis of the landmark REDUCE FMR Trial3 (the first-ever randomized, blinded, sham-controlled study in the transcatheter mitral valve space) results which highlighted a substantially higher number of patients achieved minimum clinically important differences at 12 months as compared to the sham procedure in 6MWT, ...
About the Carillon Mitral Contour System The Carillon System offers a simple right heart approach to transcatheter mitral valve repair designed to reshape the anatomy and function of the mitral apparatus from the coronary sinus. Distal and proximal anchors, connected by a shaping ribbon, utilize the heart’s venous anatomy to cinch the mitral apparatus, ...
JenaValve Technology, Inc., developer and manufacturer of differentiated pericardial transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, announces the appointment of Jane Metcalf toVice President, Regulatory Affairs and Quality, effective immediately. ...